Completed PHASE3 INTERVENTIONAL 4-arm NCT00844805

Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) (INFAST)

Infliximab as First Line Therapy in Patients With Early Active Axial Spondyloarthritis Trial

Sponsor: Merck Sharp & Dohme LLC

Conditions Ankylosing Spondylitis Axial Spondyloarthritis

Interventions Infliximab Naproxen Placebo

Updated 7 times since 2017 Last updated: Mar 15, 2017 Started: Sep 30, 2009 Primary completion: Apr 30, 2011 Completion: Sep 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00844805, this PHASE3 trial focuses on Ankylosing Spondylitis and Axial Spondyloarthritis and remains completed. Sponsored by Merck Sharp & Dohme LLC, it has been updated 7 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jun 2022 — Jul 2024 [monthly]

Completed PHASE3
Jan 2021 — Jun 2022 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.